Literature DB >> 25186383

The Octavius1500 2D ion chamber array and its associated phantoms: dosimetric characterization of a new prototype.

Ann Van Esch1, Katarzyna Basta2, Marie Evrard2, Michel Ghislain2, Francois Sergent2, Dominique P Huyskens1.   

Abstract

PURPOSE: The purpose of the study is to characterize the prototype of the new Octavius1500 (PTW, Freiburg, Germany) 2D ion chamber array, covering its use in different phantom setups, from the most basic solid water sandwich setup to the more complex cylindrical Octavius® 4D (Oct4D) (PTW) phantom/detector combination. The new detector houses nearly twice the amount of ion chambers as its predecessors (Seven29 and Octavius729), thereby tackling one of the most important limitations of ion chamber (or diode) arrays, namely the limited detector density. The 0.06 cm3 cubic ion chambers are now arranged in a checkerboard pattern, leaving no lines (neither longitudinally nor laterally) without detectors.
METHODS: All measurements were performed on a dual energy (6 MV and 18 MV) iX Clinac (Varian Medical Systems, Palo Alto, CA) and all calculations were done in the Eclipse treatment planning system (Varian) with the Anisotropic Analytical Algorithm. First, the basic characteristics of the 2D array, such as measurement stability, dose rate dependence and dose linearity were investigated in the solid water sandwich setup. Second, the directional dependence was assessed to allow the evaluation of the new Octavius2D phantom (Oct2D(1500)) for planar verification measurements of composite plans. Third, measurements were performed in the Oct4D phantom to evaluate the impact of the increased detector density on the accuracy of the volumetric dose reconstruction.
RESULTS: While showing equally good dose linearity and dose rate independence, the Octavius1500 outperforms the previous models because of its instantaneous measurement stability and its twofold active area coverage. Orthogonal field-by-field measurements immediately benefit from the increased detector density. The 3.9 cm wide compensation cavity in the new Oct2D(1500) phantom prototype adequately corrects for directional dependence from the rear, resulting in good agreement within the target dose. Discrepancies may arise towards the sides of the array because of uncompensated lateral beam incidence. The beneficial impact of the detector density is most prominent in the Oct4D system, for which the average pass rate (PR) is now nearly 100% (99.31±0.37) when using gamma criteria of 2%G,2 mm (10% dose threshold). In search of gamma analysis criteria that are not too lenient to detect possibly relevant deviations, the authors conclude that for our radiotherapy environment, the authors choose to adopt 3%L,3 mm PR97% (threshold 10%) criteria for the Oct2D(1500)/Octavius1500 system and 2%L,3 mm PR97% (threshold 10%) for the Oct4D/Octavius1500 system. These are first line pass/check criteria and plans that fail are not necessarily rejected, but submitted to a more detailed investigation.
CONCLUSIONS: When irradiated from the front, the Octavius1500 array has two main advantages over its 729 predecessors: its instantaneous measurement stability and--most importantly-its twofold detector density. In the Oct2D1500 phantom, these advantages are counterbalanced by the more pronounced directional dependence. The measurement-based 3D dose reconstruction in the Oct4D system, however, benefits considerably from the higher detector density in the checkerboard panel design.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25186383     DOI: 10.1118/1.4892178

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  8 in total

1.  Dosimetric comparison of dynamic conformal arc integrated with segment shape optimization and variable dose rate versus volumetric modulated arc therapy for liver SBRT.

Authors:  Deepak Thaper; Rose Kamal; Gaganpreet Singh; Arun S Oinam; Hanuman P Yadav; Rishabh Kumar; Vivek Kumar
Journal:  Rep Pract Oncol Radiother       Date:  2020-05-20

2.  The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma.

Authors:  Marius Treutwein; Felix Steger; Rainer Loeschel; Oliver Koelbl; Barbara Dobler
Journal:  BMC Cancer       Date:  2020-02-03       Impact factor: 4.430

3.  Patient-specific dose quality assurance of single-isocenter multiple brain metastasis stereotactic radiosurgery using PTW Octavius 4D.

Authors:  James McCulloch; Jamie Pawlowski; Neil Kirby; Karl Rasmussen; Zheng Shi; Pamela Myers; Sotirios Stathakis; Niko Papanikolaou; Daniel L Saenz
Journal:  J Appl Clin Med Phys       Date:  2020-07-18       Impact factor: 2.102

Review 4.  Novel methodologies for dosimetry audits: Adapting to advanced radiotherapy techniques.

Authors:  Marlies Pasler; Victor Hernandez; Núria Jornet; Catharine H Clark
Journal:  Phys Imaging Radiat Oncol       Date:  2018-03-19

5.  Auditing local methods for quality assurance in radiotherapy using the same set of predefined treatment plans.

Authors:  Enrica Seravalli; Antonetta C Houweling; Leo Van Battum; Thom A Raaben; Marc Kuik; Jacco A de Pooter; Marion P R Van Gellekom; Jochem Kaas; Wilfred de Vries; Erik A Loeff; Jeroen B Van de Kamer
Journal:  Phys Imaging Radiat Oncol       Date:  2018-02-02

6.  A comparative analysis of Acuros XB and the analytical anisotropic algorithm for volumetric modulation arc therapy.

Authors:  Raju P Srivastava; K Basta; Werner De Gersem; Carlos De Wagter
Journal:  Rep Pract Oncol Radiother       Date:  2021-06-09

7.  Volumetric-modulated Arc Therapy Lung Stereotactic Body Radiation Therapy Dosimetric Quality Assurance: A Comparison between Radiochromic Film and Chamber Array.

Authors:  Juan Fernando Mata Colodro; Alfredo Serna Berná; Vicente Puchades Puchades; David Ramos Amores; Miguel Alcaraz Baños
Journal:  J Med Phys       Date:  2017 Jul-Sep

8.  Practical implications for the quality assurance of modulated radiation therapy techniques using point detector arrays.

Authors:  Steffi Kantz; Almut Troeller McDermott; Matthias Söhn; Sabine Reinhardt; Claus Belka; Katia Parodi; Michael Reiner
Journal:  J Appl Clin Med Phys       Date:  2017-08-30       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.